379 results on '"P. Van Kerrebroeck"'
Search Results
52. Considerations for the management of urgency symptoms in patients with overactive bladder syndrome
53. Effects of Macroplastique® Implantation System for stress urinary incontinence and urethral hypermobility in women
54. Early Conduction Disorders After Aortic Valve Replacement With the Sutureless Perceval Prosthesis.
55. The urodynamic evaluation of lower urinary tract symptoms in men
56. Rising PSA in patients with minor LUTS without evidence of prostatic carcinoma: a missing link?
57. Alterations to network of NO/cGMP-responsive interstitial cells induced by outlet obstruction in guinea-pig bladder
58. Patient-perceived outcomes in the treatment of stress urinary incontinence: focus on urethral injection therapy
59. Bekkenfysiotherapie bij onvrijwillig urineverlies
60. Treatment of stress urinary incontinence: recent developments in the role of urethral injection
61. Treatment of overactive bladder: long-term tolerability and efficacy of tolterodine
62. The Development of a Detection Method Discriminating for Mannosylerythritol Lipids and Acylglycerols
63. Sacral neuromodulation as a treatment for neuropathic clitoral pain after abdominal hysterectomy
64. Selective detrusor activation by sacral ventral nerve-root stimulation: results of intraoperative testing in humans during implantation of a Finetech-Brindley system
65. Clinical results of sacral neuromodulation for chronic voiding dysfunction using unilateral sacral foramen electrodes
66. Micturition disturbances in multiple sclerosis: Diagnostic and treatment options
67. Intradural sacral rhizotomies and implantation of an anterior sacral root stimulator in the treatment of neurogenic bladder dysfunction after spinal cord injury: Surgical technique and complications
68. 9 Sacrale neuromodulatie: het sturen van patiëntenselectie middels urodynamica
69. The effect of indomethacin on the muscarinic induced contractions in the isolated normal guinea pig urinary bladder
70. Affective symptoms and quality of life in patients with voiding or storage dysfunction - results before and after sacral neuromodulation
71. Nouveau système de neuromodulation des racines sacrées rechargeables pour le traitement de l’hyperactivité vésicale idiopathique : résultats à 12 mois d’un essai clinique, prospectif, multicentrique
72. Correlations among improvements in urgency urinary incontinence, health-related quality of life, and perception of bladder-related problems in incontinent subjects with overactive bladder treated with tolterodine or placebo
73. Sacrale neuromodulatie voor nietobstructieve urineretentie met een voorgeschiedenis van blaasoverdistensie groter dan 1500 cc
74. Sacrale neuromodulatie voor idiopathisch overactieve blaasklachten na initiële behandeling met botulinetoxine
75. Reprogramming Sacral Neuromodulation for Sub‐Optimal Outcomes: Evidence and Recommendations for Clinical Practice
76. Treatment of overactive bladder with a miniaturized rechargeable sacral neuromodulation system
77. Hypersexuality: An important urological problem and cause of death in the French Valois kings
78. Is there a place for the assessment of bladder sensations to determine success of test stimulation in sacral neuromodulation in patients with overactive bladder?
79. Un système de neuromodulation sacré rechargeable pour le traitement de l’hyperactivité vésicale : résultats intermédiaires d’un essai clinique, prospectif, multicentrique
80. Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies
81. Neurostimulation and Neuromodulation for the Treatment for the Underactive Bladder
82. Sacral Neuromodulation as a Treatment for Chronic Pelvic Pain
83. Thinking beyond the bladder: antidiuretic treatment of nocturia
84. What treatment should we use if drugs fail for OAB; and, what really works after drugs?
85. Le point sur les traitements de seconde ligne de l’hyperactivité vésicale idiopathique
86. Overactive Bladder and Continence Guidelines: implementation, inaction or frustration?
87. The localization of cyclo-oxygenase immuno-reactivity (COX I-IR) to the urothelium and to interstitial cells in the bladder wall
88. Overactive bladder: the importance of new guidance
89. CLINICAL EXPERIENCES WITH DESMOPRESSIN FOR LONG-TERM TREATMENT OF NOCTURIA
90. Duloxetine: an innovative approach for treating stress urinary incontinence
91. EDITORIAL COMMENT.
92. Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies
93. The role of neuromodulation in the management of urinary urge incontinence
94. The standardization of terminology in nocturia: report from the standardization subcommittee of the International Continence Society
95. Efficacy of desmopressin in the treatment of nocturia: a double-blind placebo-controlled study in men
96. Experience with the long-term use of desmopressin for nocturnal enuresis in children and adolescents
97. The Efficacy and Safety of a New Once-a-Day Formulation of an α-Blocker
98. Efficacy and Safety of a New Prolonged Release Formulation of Alfuzosin 10 mg Once Daily versus Alfuzosin 2.5 mg Thrice Daily and Placebo in Patients with Symptomatic Benign Prostatic Hyperplasia
99. Standardization and terminology of nocturia
100. Clinical results of sacral neuromodulation for chronic voiding dysfunction using unilateral sacral foramen electrodes
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.